Regulatory Axsome receives FDA approval for Auvelity to treat Alzheimer’s agitation Pharmaceutical Business ReviewAuvelity is a first-in-class therapy targeting both N-methyl D-aspartate (NMDA) and sigma-1 receptors for this indication.NeuroscienceRead full story pharminent May 1, 2026 (Last updated: May 1, 2026) Pharmaceutical Business Review Auvelity is a first-in-class therapy targeting both N-methyl D-aspartate (NMDA) and sigma-1 receptors for this indication. Neuroscience Read full story Post navigation Previous: LEO Pharma to acquire gene therapy company ReplayNext: FDA’s ODAC delivers one loss, one win for AstraZeneca Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026